Abstract
Managing the transition from the new paradigm of in-process control using continuous biofluorescent particle counters from the traditional growth-based air monitoring is a difficult challenge requiring a comprehensive regulatory strategy. This is best approached within confines of the concept of process analytical technology. A five-stage approach to the evaluation, validation, test runs and data analysis, regulatory approval, and implementation is recommended. Critical to the implementation is the application of the safe harbor concept to avoid non-compliance issues.
- Process analytical technology
- biofluorescent particle counters
- in-process monitoring
- release testing
- regulatory strategy
- safe harbor concept
- Received July 31, 2025.
- Revision received November 7, 2025.
- Revision received September 10, 2025.
- Accepted November 10, 2025.
- Copyright © 2025, Parenteral Drug Association
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.






